Alimera sciences receives $20 million from ocumension therapeutics

Atlanta, april 14, 2021 (globe newswire) -- alimera sciences, inc. (nasdaq: alim) (alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmic pharmaceuticals, announced today that ocumension therapeutics (ocumension), a company focused on developing and commercializing innovative ophthalmology therapies in china and asia, has acquired an exclusive license agreement for alimera's 0.19mg fluocinolone acetonide intravitreal implant, which alimera markets elsewhere under the trademark iluvien®. the license grants ocumension the rights to develop and commercialize the product for the treatment of diabetic macular edema and other retina diseases (excluding uveitis) in the greater china territory and other western pacific countries under ocumension's own distinct trademark. additionally, ocumension has made a $10 million equity investment in alimera via a private offering.
ALIM Ratings Summary
ALIM Quant Ranking